Drug
Troriluzole clinical trials
Also written BHV-4157, FC-4157 and Trigriluzole.
- studies test it
- 12
- open now
- 2
- in phase 3
- 9
- first study started
- 2016
Keep track of what changes. Save the troriluzole studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
12 studies that test it; most in 2019 (3)
| Year | Studies |
|---|---|
| 2016 | 1 |
| 2017 | 2 |
| 2018 | 1 |
| 2019 | 3 |
| 2020 | 1 |
| 2021 | 3 |
| 2025 | 1 |
By phase
A phase 1/2 study counts in both.
- Early Phase 1
- 1
- Phase 2
- 5
- Phase 3
- 9
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 8 · Other 4
Biohaven Pharmaceuticals, Inc. (8) · University of California, Los Angeles (1) · Global Coalition for Adaptive Research (1) · Ugonma Chukwueke (1) · Dana-Farber Cancer Institute (1)
Often tested with
Tested in the same studies.
Regorafenib (1) · GDC-0084 (1) · Dianhydrogalactitol (1) · TSP-1 Activator VT1021 (1) · Pegargiminase (1) · AZD1390 (1) · Tinostamustine (1)
Studies
Open first, then newest update. How each study uses troriluzole is read from its arms, and is right about nine times in ten.
Testing it · 12
- A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent GlioblastomaRecruitingPhase 2/3Global Coalition for Adaptive ResearchNCT03970447Written as Troriluzole
- A Surgical Window of Opportunity Clinical Trial of Troriluzole in Recurrent IDH Wild-Type GlioblastomaRecruitingEarly Phase 1Ugonma ChukwuekeNCT06552260Written as Troriluzole
- Troriluzole in Adult Participants With Spinocerebellar AtaxiaActive, not recruitingPhase 3Biohaven Pharmaceuticals, Inc.NCT03701399Written as troriluzole
- A Study to Evaluate the Efficacy and Safety of Adjunctive Troriluzole in Obsessive-Compulsive DisorderCompletedPhase 3Biohaven Pharmaceuticals, Inc.NCT04693351Written as Troriluzole
- Long-term Safety Study of Adjunctive Troriluzole in Subjects With Obsessive Compulsive DisorderTerminatedPhase 3Biohaven Pharmaceuticals, Inc.NCT04708834Written as Troriluzole (BHV-4157)
- Troriluzole (BHV-4157) in Adult Participants With Obsessive Compulsive DisorderCompletedPhase 2/3Biohaven Pharmaceuticals, Inc.NCT03299166Written as Troriluzole
- Efficacy and Safety Study of Adjunctive Troriluzole in Obsessive Compulsive DisorderCompletedPhase 3Biohaven Pharmaceuticals, Inc.NCT04641143Written as Troriluzole
- Trial in Adult Participants With Spinocerebellar Ataxia (SCA)CompletedPhase 2/3Biohaven Pharmaceuticals, Inc.NCT02960893Written as Troriluzole
- Open Pilot Trial of BHV-4157Active, not recruitingPhase 3University of California, Los AngelesNCT03408080Written as BHV-4157
- Randomized Trial of Adult Participants With Generalized Anxiety DisorderCompletedPhase 3Biohaven Pharmaceuticals, Inc.NCT03829241Written as Troriluzole
- Troriluzole or Placebo Plus Ipi Plus Nivo in Mel Brain MetsTerminatedPhase 2Dana-Farber Cancer InstituteNCT04899921Written as Troriluzole
- Study of BHV-4157 in Alzheimer's DiseaseCompletedPhase 2Biohaven Pharmaceuticals, Inc.NCT03605667Written as troriluzole
Codes
What other systems call troriluzole · ClinicalTrials.gg INT017865
- UNII (FDA) S7H48S6K7HTRORILUZOLEConfirmed FDA, Wikidata
- Wikidata Q56407722troriluzoleConfirmed FDA, Wikidata
- NCI Thesaurus C142847TroriluzoleOne source FDA
- DrugBank DB15079One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | S7H48S6K7H | TRORILUZOLE | Confirmed FDA, Wikidata |
| Wikidata | Q56407722 | troriluzole | Confirmed FDA, Wikidata |
| NCI Thesaurus | C142847 | Troriluzole | One source FDA |
| DrugBank | DB15079 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.